title: Mechanisms of compensatory beta-cell growth in insulin-resistant rats: roles of Akt kinase.
abstract: The physiological mechanisms underlying the compensatory growth of beta-cell mass in insulin-resistant states are poorly understood. Using the insulin-resistant Zucker fatty (fa/fa) (ZF) rat and the corresponding Zucker lean control (ZLC) rat, we investigated the factors contributing to the age-/obesity-related enhancement of beta-cell mass. A 3.8-fold beta-cell mass increase was observed in ZF rats as early as 5 weeks of age, an age that precedes severe insulin resistance by several weeks. Closer investigation showed that ZF rat pups were not born with heightened beta-cell mass but developed a modest increase over ZLC rats by 20 days that preceded weight gain or hyperinsulinemia that first developed at 24 days of age. In these ZF pups, an augmented survival potential of beta-cells of ZF pups was observed by enhanced activated (phospho-) Akt, phospho-BAD, and Bcl-2 immunoreactivity in the postweaning period. However, increased beta-cell proliferation in the ZF rats was only detected at 31 days of age, a period preceding massive beta-cell growth. During this phase, we also detected an increase in the numbers of small beta-cell clusters among ducts and acini, increased duct pancreatic/duodenal homeobox-1 (PDX-1) immunoreactivity, and an increase in islet number in the ZF rats suggesting duct- and acini-mediated heightened beta-cell neogenesis. Interestingly, in young ZF rats, specific cells associated with ducts, acini, and islets exhibited an increased frequency of PDX-1+/phospho-Akt+ staining, indicating a potential role for Akt in beta-cell differentiation. Thus, several adaptive mechanisms account for the compensatory growth of beta-cells in ZF rats, a combination of enhanced survival and neogenesis with a transient rise in proliferation before 5 weeks of age, with Akt serving as a potential mediator in these processes.
authors.affiliation: Division of Endocrinology, Diabetes and Metabolism, University of Vermont College of Medicine, Department of Medicine, Given C331, Burlington, VT 05405, USA. thomas.jetton@.uvm.edu
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Jetton
authors.forename: James
authors.initials: J
authors.lastname: Lausier
authors.forename: Kyla
authors.initials: K
authors.lastname: LaRock
authors.forename: Winifred E
authors.initials: WE
authors.lastname: Trotman
authors.forename: Brooke
authors.initials: B
authors.lastname: Larmie
authors.forename: Aida
authors.initials: A
authors.lastname: Habibovic
authors.forename: Mina
authors.initials: M
authors.lastname: Peshavaria
authors.forename: Jack L
authors.initials: JL
authors.lastname: Leahy
mesh_terms: D000375:Aging; D000818:Animals; D002454:Cell Differentiation; D002455:Cell Division; D002470:Cell Survival; D018398:Homeodomain Proteins / Q000032:analysis; D020287:In Situ Nick-End Labeling; D007333:Insulin Resistance; D007515:Islets of Langerhans / Q000737:chemistry / Q000473:pathology*; D008297:Male; D009765:Obesity / Q000473:pathology*; D017346:Protein Serine-Threonine Kinases / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000032:analysis / Q000378:metabolism / Q000502:physiology*; D051057:Proto-Oncogene Proteins c-akt; D051381:Rats; D011924:Rats, Zucker; D015398:Signal Transduction; D015534:Trans-Activators / Q000032:analysis
chemical_list: D018398:Homeodomain Proteins; D011518:Proto-Oncogene Proteins; D015534:Trans-Activators; C084010:pancreatic and duodenal homeobox 1 protein; C494920:Akt1 protein, rat; D017346:Protein Serine-Threonine Kinases; D051057:Proto-Oncogene Proteins c-akt